[Contribution to the pharmacodynamic study of 1,2-diphenyl-3,5-dioxo-4-n-butyl-pyrazolidinopiperazine].
D000700:Analgesics / Q000494:pharmacology* / Q000633:toxicity; D000707:Anaphylaxis / Q000517:prevention & control; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology* / Q000633:toxicity; D001794:Blood Pressure / Q000187:drug effects; D004231:Diuresis / Q000187:drug effects; D004285:Dogs; D004487:Edema / Q000517:prevention & control; D006168:Guinea Pigs; D051379:Mice; D010653:Phenylbutazone / Q000494:pharmacology; D010879:Piperazines / Q000494:pharmacology* / Q000633:toxicity; D011720:Pyrazoles / Q000494:pharmacology* / Q000633:toxicity; D051381:Rats; D012119:Respiration / Q000187:drug effects; D013276:Stomach Ulcer / Q000517:prevention & control; D014882:Water-Electrolyte Balance / Q000187:drug effects
D000700:Analgesics; D000893:Anti-Inflammatory Agents; D010879:Piperazines; D011720:Pyrazoles; D010653:Phenylbutazone
Contribution à l'étude pharmacodynamique du 1-2. diphenyl.3.5. dioxo. 4.n. butylpyrrazolidine de pipérazine.